Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?

Gains in event-free and overall survival from the KEYNOTE-522 trial have incorporated pembrolizumab into the neoadjuvant and adjuvant armamentarium for stage II-III triple-negative breast cancer (TNBC). However, the lack of a second randomization to pembrolizumab after surgery raises the question of whether the adjuvan...

V. Liutti, H. Wildiers, G. Sonke et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.